Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 3/20 | 0.36 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.36 |
| ▸ | HTR1A | P08908 | 3/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4612499 | 0.89 | PARP1 (0.47) | TDP1PARP1NR3C1CA2PGR | |
| SCHEMBL14070892 | 0.82 | CTNNB1 (0.40) | PARP1NR3C1PGRNR3C2HTR1A | |
| SCHEMBL12869360 | 0.76 | CA2 (0.38) | TDP1ATMCA2HTR1AGABRA1 | |
| SCHEMBL24126748 | 0.76 | ATM (0.35) | TDP1ATM | |
| SCHEMBL435085 | 0.76 | PARP1 (0.41) | PARP1HTR1ATSHRALDH1A1ALOX12 | |
| SCHEMBL6554491 | 0.75 | PARP1 (0.49) | PARP1NR3C1CA2PGRNR3C2 | |
| SCHEMBL24243099 | 0.75 | SSTR4 (0.51) | — | |
| SCHEMBL19810406 | 0.74 | PTGS1 (0.42) | TDP1ATMNR3C1CA2PGR | |
| SCHEMBL12505563 | 0.72 | NR3C1 (0.48) | PARP1NR3C1PGRNR3C2PTGS1 | |
| SCHEMBL12572001 | 0.72 | PTGS1 (0.41) | TDP1ATMNR3C1PGRNR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228484-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-11 | — | — | US | disclosed |
| US-20240228484-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-11 | — | — | US | disclosed |
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-20230242531-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-03 | — | — | US | disclosed |
| US-11648254-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling | KUMQUAT BIOSCIENCES INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-11 | — | — | US | disclosed |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-11 | — | — | US | disclosed |
| US-20230041518-A1 | QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
| US-20220332713-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-10-20 | — | — | US | disclosed |
| US-20150005329-A1 | DISUBSTITUTED 5-FLUORO PYRIMIDINE DERIVATIVES CONTAINING A SULFOXIMINE GROUP | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-01-01 | — | — | US | disclosed |
| US-8916557-B2 | Substituted 4-Aryl-N-phenyl-1,3,5-triazin-2-amines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-12-23 | — | — | US | disclosed |
| US-20140315906-A1 | 4-ARYL-N-PHENYL-1,3,5-TRIAZIN-2-AMINES CONTAINING A SULFOXIMINE GROUP | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-10-23 | — | — | US | disclosed |
| US-20140303151-A9 | Inhibitors of PI3K-Delta and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2014-10-09 | — | — | US | disclosed |
| US-20140228387-A1 | DISUBSTITUTED 5-FLUORO-PYRIMIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-08-14 | — | — | US | disclosed |
| US-20140045852-A1 | SUBSTITUTED 4-ARYL-N-PHENYL-1,3,5-TRIAZIN-2-AMINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-02-13 | — | — | US | disclosed |
| US-20140045825-A1 | Inhibitors of PI3K-Delta and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2014-02-13 | — | — | US | disclosed |
| WO-2013096226-A1 | TRPV1 ANTAGONISTS | ABBVIE INC. (US) | 2013-06-27 | — | — | WO | disclosed |
| EP-0907646-B1 | DIHYDROBENZOPYRAN AND RELATED COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | UNIV VANDERBILT (US) | 2003-05-21 | — | — | EP | disclosed |
| US-6110960-A | FOR TREATING ARTHRITIS AND AS ANALGESIC | THE PROCTER & GAMBLE COMPANY (US) | 2000-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045852-A1 | SUBSTITUTED 4-ARYL-N-PHENYL-1,3,5-TRIAZIN-2-AMINES | PAH, NAT1, H1-5 | TDP1 419/4885ATM 2189/4885PARP1 358/4885 |
| US-11648254-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling | KRAS, NRAS, BRAF | TDP1 558/4885ATM 654/4885PARP1 856/4885 |
| US-20220332713-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | TDP1 1034/4885ATM 2805/4885PARP1 2910/4885 |
| US-20230242531-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | TDP1 1309/4885ATM 2897/4885PARP1 2550/4885 |
| US-20240228484-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, PNLIP | TDP1 1064/4885ATM 3140/4885PARP1 3014/4885 |
| US-20140303151-A9 | Inhibitors of PI3K-Delta and Methods of Their Use and Manufacture | PIK3CD, PIK3CA, PIK3R5 | TDP1 1688/4885ATM 975/4885PARP1 1685/4885 |
| US-20230041518-A1 | QUINOLINE DERIVATIVES | CFTR, NQO1, IRF3 | TDP1 2395/4885ATM 2237/4885PARP1 1100/4885 |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | TDP1 1034/4885ATM 2805/4885PARP1 2910/4885 |
| US-20140315906-A1 | 4-ARYL-N-PHENYL-1,3,5-TRIAZIN-2-AMINES CONTAINING A SULFOXIMINE GROUP | PAH, NAT1, SULT2A1 | TDP1 815/4885ATM 2490/4885PARP1 657/4885 |
| US-20140045825-A1 | Inhibitors of PI3K-Delta and Methods of Their Use and Manufacture | PIK3CD, PIK3CA, PIK3R5 | TDP1 1688/4885ATM 975/4885PARP1 1685/4885 |
| US-20140228387-A1 | DISUBSTITUTED 5-FLUORO-PYRIMIDINES | DPYD, DHFR, TYMP | TDP1 166/4885ATM 3062/4885PARP1 351/4885 |
| US-20150005329-A1 | DISUBSTITUTED 5-FLUORO PYRIMIDINE DERIVATIVES CONTAINING A SULFOXIMINE GROUP | DHFR, DPYD, TYMP | TDP1 609/4885ATM 3058/4885PARP1 654/4885 |
| US-11820766-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | TDP1 1034/4885ATM 2805/4885PARP1 2910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.